Pathogenesis and management of postprandial hyperglycemia: Role of incretin-based therapies

International Journal of General Medicine

Volumn 6, Issue , 2013, Pages 877-895

  Gerich, John ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Dipeptidyl peptidase 4; Glucagon like peptide 1; Postprandial hyperglycemia; Type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DUTOGLIPTIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PLACEBO; VILDAGLIPTIN;

ADD ON THERAPY; GASTROINTESTINAL TOXICITY; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PATIENT CARE; POSTPRANDIAL HYPERGLYCEMIA; REVIEW; RHINOPHARYNGITIS; UNSPECIFIED SIDE EFFECT;

EID: 84889255593     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S51665     Document Type: Review

References (149)

1. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev. 1998;19(4):491-503.
2. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46(1):3-19.
3. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: pathogenesis and treatment. Lancet. 2008;371(9631):2153-2156.
4. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 2003;163(11):1306-1316.
5. Peter R, Okoseime OE, Rees A, Owens DR. Postprandial glucose-a potential therapeutic target to reduce cardiovascular mortality. Curr Vasc Pharmacol. 2009;7(1):68-74.
6. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care. 2007;30(2):263-269.
7. Tibaldi J. Importance of postprandial glucose levels as a target for glycemic control in type 2 diabetes. South Med J. 2009;102(1):60-66.
8. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011;34 Suppl 1:S11-S61.
9. Woerle HJ, Neumann C, Zschau S, etal. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280-285.
10. International Diabetes Federation. IDF guideline for management of postmeal glucose. Available from: http://www.idf.org/webdata/docs/Guideline_PMG_final.pdf. Accessed October 26, 2012.
11. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20studies of 95,783individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233-240.
12. Lin HJ, Lee BC, Ho YL, etal. Postprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the nondiabetic population. Diabetes Care. 2009;32(9):1721-1726.
13. Gallwitz B. Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines. Diabetes Care. 2009; 32 Suppl 2:S322-S325.
14. Ceriello A, Bortolotti N, Motz E, etal. Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care. 1998;21(9):1529-1533.
15. Ceriello A, Bortolotti N, Motz E, etal. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism. 1999;48(12):1503-1508.
16. Ceriello A, Taboga C, Tonutti L, etal. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short-and long-term simvastatin treatment. Circulation. 2002; 106(10):1211-1218.
17. Inzucchi SE, Bergenstal RM, Buse JB, etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
18. International Diabetes Federation. IDF guidelines for management of postmeal glucose in patients with diabetes. Available from: http://www.idf.org/sites/default/files/postmeal%20glucose%20guidelines.pdf. Accessed June 6, 2013.
19. Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs. 2009;18(10): 1495-1503.
20. Meyer C, Woerle HJ, Dostou JM, Welle SL, Gerich JE. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab. 2004;287(6):E1049-E1056.
21. Mitrakou A, Kelley D, Mokan M, etal. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med. 1992;326(1):22-29.
22. Woerle HJ, Szoke E, Meyer C, etal. Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab. 2006;290(1):E67-E77.
23. Gerich JE. Postprandial hyperglycemia and cardiovascular disease. Endocr Pract. 2006;12 Suppl 1:47-51.
24. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care. 2003;26(3):881-885.
25. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1c levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508-2514.
26. van Haeften TW, Pimenta W, Mitrakou A, etal. Relative contributions of beta-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism. 2000;49(10):1318-1325.
27. Ceriello A. 25 years of progress in type 2 diabetes. Medicographia. 2011;33:29-34.
28. Ceriello A. Does postprandial blood glucose matter and why? Endocrinol Nutr. 2009;56 Suppl 4:8-11.
29. Node K, Inoue T. Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol. 2009;8:23.
30. Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care? Diabetes Care. 2011;34 Suppl 2:S120-S127.
31. Defronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53(7):1270-1287.
32. Ceriello A, Cavarape A, Martinelli L, etal. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med. 2004;21(2):171-175.
33. Esposito K, Giugliano D, Nappo F, Marfella R; for the Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110(2):214-219.
34. Holman RR, Haffner SM, McMurray JJ, etal. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1463-1476.
35. Gribble FM, Manley SE, Levy JC. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166). Diabetes Care. 2001;24(7):1221-1225.
36. Raz I, Wilson PW, Strojek K, etal. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009;32(3):381-386.
37. Ceriello A. Postprandial hyperglycemia and cardiovascular disease: is the HEART2D study the answer? Diabetes Care. 2009;32(3): 521-522.
38. Cohen A, Horton ES. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. Curr Med Res Opin. 2007;23(4):905-917.
39. Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes-a comprehensive review. Diabetes Technol Ther. 2010;12(1):11-24.
40. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705.
41. Aryangat AV, Gerich JE. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. Vasc Health Risk Manag. 2010;6: 145-155.
42. Nicolaus M, Brodl J, Linke R, Woerle HJ, Goke B, Schirra J. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab. 2011;96(1):229-236.
43. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003). 2009;49 Suppl 1:S16-S29.
44. Vollmer K, Gardiwal H, Menge BA, etal. Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans. J Clin Endocrinol Metab. 2009;94(4):1379-1385.
45. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3): 153-165.
46. Farilla L, Bulotta A, Hirshberg B, etal. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144(12):5149-5158.
47. Perfetti R, Hui H. The role of GLP-1in the life and death of pancreatic beta cells. Horm Metab Res. 2004;36(11-12):804-810.
48. Campbell RK, Cobble ME, Reid TS, Shomali ME. Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. J Fam Pract. 2010;59(9 Suppl 1):S5-S9.
49. Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009;160(6):909-917.
50. Nathan DM, Buse JB, Davidson MB, etal. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
51. McCulloch DK. Management of persistent hyperglycemia in type 2 diabetes mellitus. Available from: http://www.uptodate.com/contents/management-of-persistent-hyperglycemia-in-type-2-diabetes-mellitus?source=search_result&search=management+of+persistent+hyperglycemia+in+type+2+diabetes&selectedTitle=1%7E150. Accessed October 26, 2012.
52. Byetta® (exenatide) injection [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc; 2010.
53. BYDUREON™ (exenatide extended-release for injectable suspension) [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc; 2012.
54. Victoza® (liraglutide [rDNA origin] injection) [package insert]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2012.
55. Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med. 2010;122(3): 71-80.
56. Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis. 2010;212(1): 217-222.
57. Cervera A, Wajcberg E, Sriwijitkamol A, etal. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008;294(5):E846-E852.
58. Apovian CM, Bergenstal RM, Cuddihy RM, etal. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med. 2010;123(5):468. e9-e17.
59. Moretto TJ, Milton DR, Ridge TD, etal. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448-1460.
60. Gao Y, Yoon KH, Chuang LM, etal. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract. 2009;83(1):69-76.
61. Brodows RG, Qu Y, Johns D, Kim D, Holcombe JH. Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes. Curr Med Res Opin. 2008;24(5): 1395-1397.
62. Bunck MC, Corner A, Eliasson B, etal. One-year treatment with exenatide vs insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis. 2010;212(1): 223-229.
63. Schwartz SL, Ratner RE, Kim DD, etal. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther. 2008;30(5):858-867.
64. Buse JB, Bergenstal RM, Glass LC, etal. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103-112.
65. Drucker DJ, Buse JB, Taylor K, etal. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240-1250.
66. Blevins T, Pullman J, Malloy J, etal. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301-1310.
67. Diamant M, Van GL, Stranks S, etal. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234-2243.
68. Bergenstal RM, Wysham C, MacConell L, etal. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431-439.
69. Taylor K, Gurney K, Han J, Pencek R, Walsh B, Trautmann M. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocr Disord. 2011;11:9.
70. Wysham C, Bergenstal R, Malloy J, etal. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med. 2011;28(6):705-714.
71. Edavalath M, Stephens JW. Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives. Patient Prefer Adherence. 2010;4:61-68.
72. Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther. 2011;28(3):213-226.
73. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;81(2):161-168.
74. Garber A, Henry R, Ratner R, etal. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473-481.
75. Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(4):341-347.
76. Buse JB, Rosenstock J, Sesti G, etal. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.
77. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010;33(2): 428-433.
78. Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010;164(2-3):58-64.
79. Ratner RE, Rosenstock J, Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med. 2010;27(9):1024-1032.
80. Riddle MC, Aronson R, Home P, etal. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36(9):2489-2496.
81. Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (Getgoal-P). Diabetes Obes Metab. 2013;15(11):1000-1007.
82. Riddle MC, Forst T, Aronson R, etal. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013;36(9): 2497-2503.
83. Barnett AH. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evid. 2011;6:67-79.
84. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care. 2012;35(6):1225-1231.
85. Seino Y, Min KW, Niemoeller E, Takami A. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14(10):910-917.
86. Ratner R, Hanefeld M, Shamanna P, etal. Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea ± metformin (GetGoal-S). Diabetologia. 2011;54:S317.
87. Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther. 2013;30(2):81-101.
88. Matthews JE, Stewart MW, De Boever EH, etal. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(12):4810-4817.
89. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009;32(10):1880-1886.
90. Hassan M, Eskilsson A, Nilsson C, etal. In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera. Nucl Med Biol. 1999;26(4):413-420.
91. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci. 2002;18(1-2):7-14.
92. Kastin AJ, Akerstrom V. Entry of exendin-4into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord. 2003;27(3): 313-318.
93. McClean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci. 2011;31(17):6587-6594.
94. Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes. 2004;53(9):2492-2500.
95. Rosenstock J, Ahren B, Chow FC, etal. Once-weekly GLP-1 receptor agonist albiglutide vs titrated prandial lispro added on to titrated basal insulin glargine in type 2 diabetes (T2D) uncontrolled on glargine plus oral agents: similar glycemic control with weight loss and less hypoglycemia. Diabetes. 2012;61:A15.
96. Pratley RE, Barnett AH, Feinglos MN, etal. Efficacy and safety of once-weekly (QW) albiglutide vs once-daily (QD) liraglutide in type 2 diabetes (T2D) inadequately controlled on oral agents: HARMONY 7 trial. Diabetes. 2012;61 Suppl 1.
97. Fonseca VL, Ahren B, Chow F, etal. Once weekly GLP-1 receptor agonist albiglutide vs prandial lispro added to basal glargine in type 2 diabetes: similar control with weight loss and less hypoglycemia. Poster presented at the 2012 European Association for the Study of Diabetes (EASD) Meeting, October 1-5, 2012, Berlin, Germany. 2012.
98. Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab. 2012;14(8):675-688.
99. Ahren A, Dimas L, Miossec P, etal. Efficacy and safety of lixisenatide QD morning and evening injections vs placebo in T2DM inadequately controlled on metformin (GetGoal-M). World Diabetes Congress of the International Diabetes Federation, December 4-8, 2011, Dubai, United Arab Emirates, 2011.
100. Kapitza C, Forst T, Coester HV, Poitiers F, Ruus P, Hincelin-Mery A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab. 2013;15(7):642-649.
101. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565.
102. Rodbard HW, Jellinger PS, Davidson JA, etal. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
103. Ghatak SB, Patel DS, Shanker N, Srivstava A, Deshpande SS, Panchal SJ. Alogliptin: a novel molecule for improving glycemic control in type II diabetes mellitus. Curr Diabetes Rev. 2010;6(6): 410-421.
104. Bock G, Dalla Man C, Micheletto F, etal. The effect of DPP-4inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. Clin Endocrinol (Oxf). 2010;73(2):189-196.
105. Januvia™ (sitagliptin) tablets [package insert]. Whitehouse Station, NJ: Merck and Co Inc; 2012.
106. Onglyza™ (saxagliptin) tablets [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2011.
107. Tradjenta™ (linagliptin) tablets [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2011.
108. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13(3):258-267.
109. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401-2411.
110. Nonaka K, Kakikawa T, Sato A, etal. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79(2):291-298.
111. Iwamoto Y, Taniguchi T, Nonaka K, etal. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J. 2010;57(5):383-394.
112. Taskinen MR, Rosenstock J, Tamminen I, etal. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(1):65-74.
113. Defronzo RA, Hissa MN, Garber AJ, etal. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32(9):1649-1655.
114. Stenlof K, Raz I, Neutel J, Ravichandran S, Berglind N, Chen R. Saxagliptin and metformin XR combination therapy provides glycemic control over 24hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin. 2010;26(10):2355-2363.
115. Chacra AR, Tan GH, Ravichandran S, List J, Chen R. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res. 2011;8(2):150-159.
116. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63(9):1395-1406.
117. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28(4):513-523.
118. Minervini G, Charbonnel B, Barnett AH, Monyak J, Iqbal N. Efficacy and safety of saxagliptin in combination with insulin in patients with long-standing type 2 diabetes. Abstract presented at the American Diabetes Association 72nd Scientific Sessions, June 8-12, 2012, Philadelphia, PA, 2012.
119. Vilsboll T, Rosenstock J, Yki-Jarvinen H, etal. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(2):167-177.
120. Yki-Jarvinen H, Duran-Garcia S, Pinnetti S, etal. Efficacy and safety of linagliptin as add-on therapy to basal insulin in patients with type 2 diabetes. Abstract presented at the American Diabetes Association 72nd Scientific Sessions, June 8-12, 2012, Philadelphia, PA, 2012.
121. Viereck C, Boudes P. An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development. Contemp Clin Trials. 2011;32(3):324-332.
122. Ahrén B, Foley JE, Ferrannini E, etal. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2010;33(4):730-732.
123. Derosa G, Maffioli P, Ferrari I, etal. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res. 2010;42(9):663-669.
124. Garber AJ, Foley JE, Banerji MA, etal. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008;10(11):1047-1056.
125. Lukashevich V, Kozlovski P, Foley J, Kothny W. Vildagliptin combined with insulin reduces HbA1c without increasing risk of hypoglycemia and weight gain in patients with type 2 diabetes mellitus. Abstract presented at the American Diabetes Association 72nd Scientific Sessions, June 8-12, 2012, Philadelphia, PA, 2012.
126. Covington P, Christopher R, Davenport M, etal. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008;30(3):499-512.
127. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin. 2011;27(9): 1781-1792.
128. Pattzi HM, Pitale S, Alpizar M, etal. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010;12(4):348-355.
129. Morales J. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4inhibitors. Postgrad Med. 2011;123(6):189-201.
130. Defronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24(10):2943-2952.
131. Sulistio M, Carothers C, Mangat M, Lujan M, Oliveros R, Chilton R. GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects. Curr Atheroscler Rep. 2009;11(2):93-99.
132. Pencek R, Blickensderfer A, Li Y, Brunell S, Anderson P. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012;124(4):21-32.
133. Pencek R, Brunell S, Li Y, Hoogwerf BJ, Malone J. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications. Postgrad Med. 2012;124(4):33-40.
134. Green JB. The dipeptidyl peptidase-4inhibitors in type 2 diabetes mellitus: cardiovascular safety. Postgrad Med. 2012;124(4):54-61.
135. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Aailable from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/%20Guidances/UCM071627.pdf. Accessed October 26, 2012.
136. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med. 2008;358(18):1970-1971.
137. Engel SS, Williams-Herman DE, Golm GT, etal. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract. 2010;64(7):984-990.
138. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150-156.
139. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab. 2011;96(7):2027-2031.
140. Dore DD, Seeger JD, Arnold CK. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25(4):1019-1027.
141. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33(11):2349-2354.
142. Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care. 2010;33(2):453-455.
143. Barzilai N, Guo H, Mahoney EM, etal. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(5):1049-1058.
144. Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J. Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev. 2012;28(3):268-275.
145. Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. The oral DPP-4inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(6):542-550.
146. Seck T, Nauck M, Sheng D, etal. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 2010;64(5): 562-576.
147. Stenlof K, Raz I, Neutel J, Ravichandran S, Berglind N, Chen R. Saxagliptin and metformin XR combination therapy provides glycemic control over 24hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin. 2010;26(10):2355-2363.
148. Fonseca V, Zhu T, Karyekar C, Hirshberg B. Adding saxagliptin to extended-release metformin vs uptitrating metformin dosage. Diabetes Obes Metab. 2012;14(4):365-371.
149. Ferrannini E, Fonseca V, Zinman B, etal. Fifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157-166.